Metamizole Sodium



Indications and Reactions:

Role Indications Reactions
Secondary
Product Used For Unknown Indication 43.0%
Pain 6.1%
Drug Use For Unknown Indication 5.0%
Bronchitis 4.5%
Tracheobronchitis 4.5%
Prophylaxis 3.9%
Analgesic Therapy 3.4%
Fusarium Infection 3.4%
Hypertension 3.4%
Pyrexia 3.4%
Body Temperature Increased 2.2%
Diverticulitis 2.2%
Pneumonia Bacterial 2.2%
Procedural Pain 2.2%
Pulmonary Embolism 2.2%
Thrombosis Prophylaxis 2.2%
Colon Cancer 1.7%
Sinusitis 1.7%
Type 1 Diabetes Mellitus 1.7%
Bone Pain 1.1%
Condition Aggravated 12.1%
Pyrexia 9.1%
Agranulocytosis 6.1%
Autoimmune Thrombocytopenia 6.1%
Drug Hypersensitivity 6.1%
Staphylococcal Infection 6.1%
Suicide Attempt 6.1%
Thrombocytopenia 6.1%
Toxic Epidermal Necrolysis 6.1%
Ventricular Dysfunction 6.1%
Acute Febrile Neutrophilic Dermatosis 3.0%
Angioedema 3.0%
Cholestasis 3.0%
Erythema Multiforme 3.0%
Hypochromic Anaemia 3.0%
Maternal Exposure During Pregnancy 3.0%
Multiple Drug Overdose 3.0%
Myocardial Infarction 3.0%
Pruritus 3.0%
Renal Failure Acute 3.0%
Concomitant
Pulmonary Oedema 15.8%
Renal Failure Chronic 11.0%
Drug Use For Unknown Indication 8.5%
Hypertension 7.0%
Product Used For Unknown Indication 6.3%
Pain 5.6%
Non-small Cell Lung Cancer 5.3%
Anaemia 4.3%
Premedication 3.8%
B-cell Lymphoma 3.5%
Non-hodgkin's Lymphoma 3.5%
Prophylaxis 3.5%
Prostate Cancer Metastatic 3.5%
Pain In Extremity 3.3%
Hiv Infection 3.2%
Drug Exposure During Pregnancy 2.7%
Rheumatoid Arthritis 2.5%
Cancer Pain 2.3%
Colorectal Cancer Metastatic 2.3%
Psoriatic Arthropathy 2.3%
Hepatic Enzyme Increased 11.6%
Fatigue 8.2%
Pain 6.8%
Pulmonary Oedema 6.8%
Pyrexia 6.1%
Sepsis 6.1%
Anal Fissure 5.4%
Gastritis Erosive 5.4%
Dyspnoea 4.8%
Haemorrhoids 4.8%
Varicose Vein 4.8%
Withdrawal Syndrome 4.1%
Muscle Twitching 3.4%
Pleural Effusion 3.4%
Renal Failure Acute 3.4%
Visual Impairment 3.4%
Vomiting 3.4%
Anaemia 2.7%
Colonic Polyp 2.7%
Cystitis 2.7%
Interacting
Chronic Obstructive Pulmonary Disease 100.0%
Swelling Face 50.0%
Oedema Mucosal 25.0%
Pitted Keratolysis 25.0%